News about Global Pharma

Karyopharm to Seek US FDA Accelerated Approval for Selinexor-Ruxolitinib Combination in Myelofibrosis

Karyopharm Therapeutics plans to file an sNDA with the US FDA seeking accelerated approval for selinexor in combination with ruxolitinib for myelofibrosis. Supported by positive Phase 3 SENTRY trial results, the combination has the potential to become the first approved frontline combination therapy for the rare blood cancer.

Global Pharma | 03/08/2026 | By News Bureau |  431

Kaigene Licenses Autoimmune Drug KG006 to Taisho Pharma in Japan

Taisho Pharmaceutical secures exclusive rights to clinically develop, register, and commercialise Kaigene's next-generation FcRn inhibitor, KG006, in Japan.

Global Pharma | 01/08/2026 | By News Bureau |  170

Johnson & Johnson's RYBREVANT FASPRO Gets US FDA Priority Review for Advanced Head and Neck Cancer

Johnson & Johnson's RYBREVANT FASPRO has received US Food and Drug Administration (FDA) Priority Review (PR) as a potential first-in-class subcutaneous treatment for advanced head and neck cancer.

Global Pharma | 01/08/2026 | By News Bureau |  287

Johnson & Johnson Partners with Sail Biomedicines to Advance In Vivo CAR-T Therapies

Johnson & Johnson has entered into a collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases that includes a USD 465 million equity investment, milestone-based payments and an exclusive option to acquire Sail Biomedicines for USD 2.58 billion.

Global Pharma | 31/07/2026 | By News Bureau |  168

American Regent Issues Voluntary Nationwide Recall of One Lot of Papaverine Hydrochloride Injection

American Regent has recalled one lot of Papaverine Hydrochloride Injection nationwide due to visible glass and paraformaldehyde particulate matter.

Global Pharma | 27/07/2026 | By News Bureau |  114

Sanofi to not Submit Amlitelimab in Atopic Dermatitis for Global Regulatory Reviews

Sanofi will not seek global regulatory approval for amlitelimab in Atopic Dermatitis (AD) after efficacy and safety data did not support further development.

Global Pharma | 27/07/2026 | By News Bureau |  191

US FDA Approves TYLENOL with Naproxen for OTC Use

The US Food and Drug Administration (FDA) has approved TYLENOL with Naproxen, the first OTC fixed-dose acetaminophen and naproxen combination offering up to 12 hours of pain relief.

Global Pharma | 25/07/2026 | By News Bureau |  206

Nona Biosciences Partners with Medical University of Vienna on Antibody Research

Nona Biosciences has partnered with the Medical University of Vienna to advance fully human antibody development for infectious diseases using its H2L2 Harbour Mice platform.

Global Pharma | 23/07/2026 | By News Bureau |  129

Takeda and Indonesia Partner to Expand Access to Plasma-Derived Medicines

Takeda and Indonesia have partnered to strengthen healthcare resilience, expand access to plasma-derived medicines, and establish a national plasma donation ecosystem with an initial USD 30 million investment.

Global Pharma | 13/07/2026 | By News Bureau |  141

Cipher Pharmaceuticals Secures pCPA Agreement to Expand Public Access to Epuris Across Canada

Cipher Pharmaceuticals has completed negotiations with the pan-Canadian Pharmaceutical Alliance, securing a Letter of Intent for Epuris (isotretinoin). The agreement represents a significant step toward expanding public drug plan coverage and improving patient access to severe acne treatment across Canada.

Global Pharma | 09/07/2026 | By News Bureau |  145